According to incomplete statistics, this week (February 5-February 9), a total of 10 companies in the field of medicine and health across the country have received investment and financing. Among them, Heqirui Pharmaceutical, Aikemai, Hongji Medical, Jieyi Biological, and Maikekang Biotechnology have raised more than 100 million yuan. The financing companies are involved in the clinical research of HMI-115 monoclonal antibody, the transformation of clinical prescriptions of traditional Chinese medicine, and the research and development of disposable electronic hysteroscopes and supporting disposable surgical instruments.
Biopharmaceuticals. Heqirui Pharmaceutical: Completed nearly 200 million yuan B+ round of financing.
On February 7, Heqirui Pharmaceutical announced the completion of a B+ round of financing of nearly 200 million yuan, which was co-led by Tin Venture Capital and VMS Group. This round of financing will provide strong support for the two international Phase II clinical studies of HMI-115 monoclonal antibody, the core pipeline of Heqirui, and the research and development of other product lines of the company.
EchoBio is a science-driven, clinical-stage biopharmaceutical company with R&D facilities and offices in Beijing, Shanghai and Nanjing, China. The establishment of the company is based on the in-depth understanding and decades of research results of Professor Xiao Ruiping, Dean of the School of Future Technology of Peking University, and his team.
Chinese Medical Federation: Completed the A round of financing of 10 million yuan.
On February 6, the National Medical Federation announced that it had recently completed a round of financing of 10 million yuan. This round of financing was led by Beijing Tong Ren Tang Inheritance and Innovation** Company. The funds raised will be used to promote the improvement and optimization of the company's TCM clinical prescription transformation system, and to develop the application scenarios of TCM scientific and technological achievements in clinical and out-of-hospital applications.
Tong Ren Tang Inheritance Innovation Capital is a private equity management platform under Beijing Tong Ren Tang Group, and an important foreign investment platform under Tong Ren Tang Group, mainly focusing on mergers and acquisitions and equity investment in the upstream and downstream of Tong Ren Tang Group's industrial chain, innovative drugs, medical devices, medical digitalization, medical services, and transformation of traditional Chinese medicine achievements.
Medical devices. Aikemai: Completed nearly 200 million yuan in Series A+ financing.
On February 7, Accumai announced that it had recently completed nearly 200 million yuan in Series A+ financing. This round of financing is co-led by Shaoxing Binhai New Area Biomedical Industry Equity Investment** and Shanghai Biopharmaceutical**, which are managed by Shengshi Investment, and the funds raised will be used to accelerate the R&D and registration of AccuPulse's core products, and promote the localization of pulse ablation and 3D mapping systems.
Founded in November 2020, AccuPulse is committed to becoming a platform-based innovative technology company in the field of cardiac electrophysiology, so as to improve the quality of life of patients with atrial fibrillation and other arrhythmias.
Jiyuan Medical: Completed the second phase of Series A financing of tens of millions of yuan.
On February 6, Jiyuan Medical announced that it would complete the second phase of Series A financing of tens of millions of yuan following the first phase of Series A financing in 2023. The funds raised in this round of financing will be mainly used for the research and development, global registration and certification, production and marketing of disposable electronic hysteroscopes and supporting disposable surgical instruments, so as to further expand the competitive advantage.
Founded in 2017, Jiyuan Medical focuses on the R&D, production and sales of disposable endoscopes, and is committed to creating an "overall solution for disposable endoscopes". With the disposable electronic hysteroscope as the guide, the series of disposable electronic hysteroscopes and supporting disposable surgical instruments to meet the diagnosis and treatment of the whole surgical scene of uterine cavity diseases.
Jiyuan Medical official website.
Hongji Medical: Completed hundreds of millions of yuan in financing.
On February 6, Hongji Medical successfully completed a new round of financing, with a financing amount of hundreds of millions of yuan, which was exclusively invested by Qiming Venture Partners. This round of financing will be used to continue to promote the commercial promotion of disposable endoscope products that have been marketed, as well as the R&D and production of new pipelines.
Founded in 2014, Hongji Medical is a national specialized and special new small giant enterprise focusing on the R&D, production, sales and after-sales service of medical devices. The company's products provide comprehensive solutions in the field of endoscopy for clinical surgery, emergency, anesthesia, respiratory, pediatrics, ICU, operating room, ambulance, outdoor first aid, etc.
Jieyi Biotech: Completed hundreds of millions of yuan in C+ round of financing.
On February 5, Jieyi Biotech announced that it had recently completed hundreds of millions of yuan in Series C+ financing. The investors in this round are Kuntai**, Yuhang Guotou Group and other industrial investors. This round of financing will be used for the research and development of product pipelines, the registration of medical device products, and the implementation of commercial application strategies.
Founded in 2019, based on the two cutting-edge technology routes of high-throughput sequencing (NGS) and gene editing (CRISPR CAS), Jieyi Biotech has independently developed a series of automated detection instruments, diagnostic reagents and bioinformatics analysis platforms, and obtained a number of medical device product registration certificates, building an innovative molecular diagnosis overall solution covering critical and difficult complex infections, moderate infections and common infections.
Medical services. Weimai Medical: Completed tens of millions of yuan in Series A financing.
On February 10, Weimai Medical announced the completion of tens of millions of yuan in Series A financing. This round of financing is exclusively invested by Xiamen International Trade Industry **, which is managed by Guoxing Investment, and the financing funds will be mainly used to promote product research and development and upgrading, strengthen academic promotion, and build sales systems and channels. At the same time, Weimai Medical will also continue to deepen the first brand of perioperative body temperature management and consolidate the market position of the first brand of digital vital signs management.
Weimai Medical is a high-tech enterprise group engaged in the R&D, production and sales of innovative high-end medical devices and medical services, focusing on the digital management of patients' vital signs, and providing clinics with vital signs monitoring solutions for different scenarios.
Aiqiao Medical: Completed tens of millions of yuan in Series A financing.
On February 8, Aiqiao Medical announced that it had recently completed tens of millions of yuan in Series A financing. This round of financing is jointly invested by Yuanyi Capital and Suzhou Industrial Park Science and Technology Innovation**. This round of funds will be mainly used for the company's product research and development, marketing and promotion. It is reported that Aiqiao Medical's hip digital products are in clinical trials and are expected to be approved for listing this year, and the company's new round of financing will also be launched soon.
Aiqiao Medical is a national high-tech enterprise, committed to providing the overall solution of "digital surgical system + intelligent assisted decision-making + joint cloud service platform", focusing on the R&D and production of innovative medical devices for digital bone and joint diseases, and boosting the digital transformation of joint surgery.
Wan Guiyuan: Completed nearly 50 million A+ round of financing.
On February 8, Wanguiyuan announced the completion of the A+ round of investment, led by Suzhou Innovation Investment Group. This round of financing will be mainly used to improve the full-process R&D and production service capabilities of microfluidic chip CDMO, the construction of new R&D bases, and accelerate the business expansion of Wanguiyuan in the global market.
Since its establishment, Wanguiyuan has always been committed to providing one-stop services for in vitro diagnostics, medical devices, life sciences and biopharmaceutical enterprises, including core processes, equipment and comprehensive solutions. As a total engineering solution provider, it focuses on providing customers with a full range of OEM, ODM, CMO and CDMO services such as chip design, molecular diagnostics and life science instruments, automation equipment and consumables production.
Maikekang Biotech: Completed nearly 300 million yuan in Series C financing.
On February 6, Maikekang Biotech announced the completion of nearly 300 million yuan in Series C financing. This round of financing is exclusively invested by Shenzhen Capital Group in the transformation and upgrading of manufacturing new materials**.
Maikekang is a biomedical high-tech enterprise dedicated to the research and development and industrialization of new vaccines, focusing on the research and development, production and sales of innovative vaccines and new adjuvants. It has a leading new adjuvant platform, recombinant protein expression platform and mRNA platform. The pipeline projects include a number of preventive vaccines for major infectious diseases and first-class vaccines for hepatitis B, allergic diseases and cancer, all of which are the first blockbuster varieties in China with huge market space.